Diphtheria Market Summary

• The Diphtheria Market Size is anticipated to grow with significant CAGR during the syudy period (2020-2034).
• DelveInsight’s analyst estimates that the incidence of diphtheria continues to grow in the 7MM due to the rise in birth rate and growing population, advancements in vaccine delivery devices, and expansion of global immunization programs that are further expected to increase the diphtheria market.
• Disease awareness and preparedness lead to early diagnosis, timely treatment, and vaccination uptake. Additionally, the need for outbreak preparedness in areas with limited vaccine coverage or during potential outbreaks can drive demand for diphtheria-related products and services.
• Though the diphtheria treatment market is growing at a slow pace, there is an opportunity for pharmaceutical companies to focus on improving diphtheria traditional vaccines with new formulations and improved technologies such as the use of adjuvants or novel delivery systems that can enhance vaccine efficacy, safety, and convenience, leading to increased market demand.
• Furthermore, growing cases of airborne droplet infections and increased vaccine usage due to the COVID-19 pandemic have increased diphtheria market dynamics.
• On the other hand, the major challenges that restrain the diphtheria market growth include a lack of skilled staff to treat diphtheria patients, vaccine access and affordability, and a limited diagnostic capacity. 

Request for Sample Page @ Diphtheria Market Forecast Report

Key Factors Driving Diphtheria Market:

• Rising incidence and outbreaks in developing regions: Ongoing diphtheria cases, especially in parts of South Asia, Africa, and conflict‑affected areas with lower immunization coverage are increasing demand for vaccines and treatments. 
• Expanded national and global immunization programs: Government immunization initiatives and WHO/Gavi‑backed vaccination campaigns are boosting procurement and coverage of diphtheria‑containing vaccines, driving market growth.
• Technological and formulation advancements: Innovations in vaccine technology (including combination vaccines with improved efficacy and safety) and progress in treatment options enhance adoption and expand market opportunities.
• Increasing public awareness and preventive healthcare focus: Greater public understanding of diphtheria risks and benefits of vaccination supports higher uptake of preventive vaccines and treatment interventions.
• Strengthening healthcare infrastructure and funding: Improved healthcare access, expanded cold‑chain logistics, and increased investment in infectious disease control reinforce market expansion especially in emerging economies.

DelveInsight’s report titled “Diphtheria Market Insights, Epidemiology, and Market Forecast – 2034” comprehensively analyzes diphtheria. The report includes a detailed examination of the historical and projected epidemiology data that includes incident cases of diphtheria segmented by age and type. The diphtheria market report offers an in-depth understanding of the various aspects related to the patient population, including diagnosis, prescriptions patterns, physician perspectives, market access, treatment, and future market developments for the seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2020 to 2034.

To gauge the market’s overall potential and identify business opportunities, the report discusses current diphtheria treatment practices and algorithms and unmet medical needs.

Diphtheria Treatment Market

Diphtheria Overview

Diphtheria is a highly contagious bacterial infection caused by the bacterium Corynebacterium diphtheriae. It primarily affects the respiratory system and can also cause damage to the heart, nervous system, and other organs if left untreated. The major virulence determinant of C. diphtheriae is diphtheria toxin, a bacteriophage-encoded protein. The infection is usually spread through respiratory droplets, such as coughing or sneezing, from infected individuals. Symptoms of the disease vary depending on the site of infection; however, sore throat, mild fever, and weakness are a few initial symptoms. Diphtheria most commonly affects children under the age of 5 years and adults over 70 years of age. This is primarily due to the higher chance that patients in these age groups have not had a vaccination or booster. The diagnosis is based on clinical presentation, laboratory tests, and identifying the bacteria or its toxin. Diphtheria can be prevented through vaccination. The most common vaccine used is the DTP vaccine, which protects against diphtheria, tetanus, and pertussis (whooping cough). Booster doses are recommended to maintain immunity throughout life. Further, prompt treatment is crucial for diphtheria. The primary treatment involves administering antitoxin to neutralize the diphtheria toxin and antibiotics to eradicate the bacteria.

Diphtheria Diagnosis

Diagnosing and treating diphtheria typically involves several steps, including the identification of risk factors, laboratory testing, lifestyle modifications, and, if necessary, medication interventions.

The cornerstone of diphtheria diagnosis is laboratory testing and clinical evaluation conducted to confirm the diagnosis of diphtheria. This typically involves collecting specimens from the throat or other affected areas and sending them to a laboratory for culture and identification of the bacterium C. diphtheriae.

Diphtheria Treatment Landscape

The treatment approach for diphtheria typically involves a combination of interventions to eliminate the bacterial infection, neutralize the toxin produced by the bacteria, and provide supportive care. Diphtheria antitoxin (DAT) in combination with antibiotics is used.

Diphtheria Epidemiology

The Diphtheria epidemiology section provides insights into the historical and current diphtheria patient pool and forecasted trends for seven individual major countries. It recognizes the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.

The epidemiology section of the diphtheria market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed Diphtheria patient pool, their trends, and the underlying assumptions are all included in this section of the report.

Diphtheria Epidemiology Key Findings

• “As per the World Health Organization (WHO) (2016), the incidence of diphtheria is low. Diphtheria is very rare; the incidence in 2015 was approximately 0.07 individuals per 100,000.”
• “According to the Centers for Disease Control and Prevention (CDC) (2022), the overall case-fatality rate for diphtheria is 5–10%, with higher death rates (up to 20%) among persons younger than 5 and older than 40 years of age. The incubation period is usually 2–5 days, with a range of 1–10 days.”
• “According to the American Society of Microbiology (2022), those who had received a diphtheria booster were 54% less likely, and those who had received a tetanus booster were half as likely to develop severe COVID-19.”
• “According to the European Centre for Disease Prevention and Control (ECDC) (2022), diphtheria is a rare disease in the EU/EEA. An average of 52 cases were reported annually across the EU/EEA to ECDC between 2016 and 2020. Around 50% of reported cases were caused by C. diphtheria. Of the 128 cases caused by C. diphtheriae reported between 2016 and 2020, 60 were cutaneous, 25 respiratory, and one had both a cutaneous and respiratory presentation.

Diphtheria Epidemiology Segmentation

• Incidence of Diphtheria
• Age-specific Incident Cases of Diphtheria
• Type-specific Incident Cases of Diphtheria

Diphtheria Drug Analysis

The drug chapter segment of the Diphtheria report encloses the detailed analysis of Diphtheria marketed drugs and late-stage (Phase-III and Phase-II) Diphtheria pipeline drugs. It also helps to understand the Diphtheria clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Diphtheria Marketed Drugs

VAXELIS: Sanofi Pasteur

VAXELIS, manufactured by Sanofi Pasteur, is a hexavalent vaccine or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect children against diphtheria, tetanus, pertussis, poliomyelitis, Hemophilic B, and hepatitis B, which is used in more than 90 countries around the world including in Europe, Canada, Australia, and New Zealand.

In February 2016, marketing approval in the EU was granted to Vaxelis, while in December 2018, the US FDA licensed DTaP-IPV-Hib-HepB (Vaxelis) for use as a three-dose series in infants at ages 2, 4, and 6 months.

ADACEL: Sanofi Pasteur

ADACEL, manufactured by Sanofi Pasteur, is a Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine) used in adults, adolescents, and children aged 4 years and older as a booster following primary immunization. It is a suspension for intramuscular injection.

In June 2005, ADACEL was licensed in the US for use in adults and adolescents 10–64 years of age. FDA also approved ADACEL for use during pregnancy.

Diphtheria Emerging Drugs

The currently available treatments for diphtheria aim to mitigate the complications associated with the condition. The Diphtheria market dynamics are expected to change, primarily due to increased healthcare spending worldwide. Diphtheria Market players such as GlaxoSmithKline, MassBiologics, Sanofi Pasteur, Dynavax GmbH, GC Biopharma, and others are actively involved in developing Diphtheria treatments.

GC3111: Green Cross Corporation

GC3111 is an investigational diphtheria toxin that inhibits eukaryotic protein synthesis and acts as an immune stimulant. A bacterial vaccine is administered via the intramuscular route. GC 3111A is still in Phase II trials for diphtheria, pertussis, and tetanus.

DV2-TDAP-01: Dynavax

DV2-TDAP-01, manufactured by Dynavax Technologies, is a DTaP vaccine used for tetanus, diphtheria, and pertussis. The company completed a Phase I trial, demonstrating the vaccine candidate was well tolerated without safety concerns. Additionally, immunogenicity results in adults were consistent with our expectations and supported our plan to continue advancing the vaccine program.

Note: Detailed emerging therapies assessment will be provided in the final report…

Diphtheria Market Outlook

The treatment and management of diphtheria involve a combination of vaccines and the use of medications. The diphtheria market is segmented based on the product type and treatment. Based on product type, the market already has diphtheria toxoid and pertussis (Dtap), tetanus toxoid (TT), and tetanus-diphtheria (Td), while based on treatment the use of antitoxin, antibiotics, and macrolides have been observed in patients with diphtheria.

Vaccination is the primary approach to prevent diphtheria and is usually administered as part of a combination vaccine, such as the DTP vaccine (diphtheria, tetanus, pertussis). The vaccine stimulates the immune system to produce antibodies against the diphtheria toxin, providing immunity against the disease. Multiple vaccine doses are recommended, typically starting in infancy and followed by booster doses throughout life. For individuals diagnosed with diphtheria, treatment often involves the use of diphtheria antitoxin (DAT). DAT is derived from the blood of animals immunized against diphtheria toxin and contains antibodies that neutralize the toxin produced by the bacteria. DAT administration can help prevent the spread of the toxin and reduce the severity of the disease.

Alongside DAT, antibiotics are also prescribed to treat diphtheria. Antibiotics, such as penicillin or erythromycin, are used to eliminate the bacteria from the body, reduce transmission to others, and prevent complications. Antibiotic treatment is usually administered for a specified duration, depending on the severity of the infection and the individual’s response. Moreover, an early diagnosis and prompt initiation of treatment can manage diphtheria. A specific treatment regimen is based on the severity of the disease and individual patient factors.

According to DelveInsight, the Diphtheria market in the 7MM is expected to change significantly during the study period 2020–2034.

Diphtheria Market Segmentation

DelveInsight’s ‘Diphtheria Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future diphtheria market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Diphtheria Market Size by Countries

The total Diphtheria market size is analyzed for individual countries (the United States Market, EU4 (Germany, France, Italy, and Spain) and the UK market, and Japan). The United States accounted for a larger portion of the 7MM market for diphtheria in 2022 due to the high incidence of the condition and the higher cost of treatments. With the potential early entry of new products, this dominance is predicted to continue.

Diphtheria Market Size by Therapies

To depict each nation’s distinct historical and projected market shares, the diphtheria market is separated by therapies and medication classes. Ongoing research focuses on a novel mode of action to improve the quality of life for individuals with diphtheria.

The market for diphtheria therapies includes vaccines, such as the DTP vaccine (diphtheria, tetanus, pertussis), and medications used to treat diphtheria, such as diphtheria antitoxin and antibiotics.

Despite the presence of marketed vaccines, diphtheria and other infections caused by potentially toxigenic corynebacteria continue to play major roles as a lethal resurgent infectious disease.

However, educating patients and creating awareness with improved vaccine access and affordability can improve diphtheria market growth.

Note: Detailed market segment assessment will be provided in the final report…

Diphtheria Market Access and Reimbursement

DelveInsight’s ‘Diphtheria Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of diphtheria.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views on Diphtheria Market Report

To keep up with current Diphtheria market trends and fulfill gaps in secondary findings, we interview KOLs and SMEs’ working in the Diphtheria domain. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or diphtheria market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the diphtheria unmet needs.

Diphtheria KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Nantes Université in France, the Department of Immunology and Respiratory at Duke University Medical Center, and Durham in the US.

“There are four kinds of vaccines available to provide protection against DT (diphtheria and tetanus) in the US, so it is recommended that children who received four doses before their fourth birthday receive a fifth dose of DTaP (diphtheria, tetanus, and acellular pertussis) vaccine before starting school.”

“Lifestyle modifications, including adopting face masks and regular sanitization after the pandemic, has been a common approach against all airborne droplet diseases, including Diphtheria.”

Note: Detailed assessment of KOL Views will be provided in the full report of diphtheria…

DiphtheriaCompetitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Diphtheria Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Diphtheria Drugs Uptake

This section focuses on the rate of uptake of the Diphtheria drugs recently launched in the Diphtheria market or expected to get launched in the market during the study period 2020-2034. The analysis covers Diphtheria market uptake by drugs; patient uptake by therapies; and sales of each drug.

Diphtheria Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Diphtheria market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Diphtheria Pipeline Development Activities

The Diphtheria pipeline report provides insights into Diphtheria Clinical Trials within Phase II and Phase III stages. It also analyses Diphtheria Companies involved in developing targeted therapeutics.

Diphtheria Pipeline Activities

The Diphtheria clinical trials analysis report covers information on collaborations, acquisitions and mergers, licensing, patent details, and other information for emerging diphtheria therapies.

Scope of the Diphtheria Market Report

• The report covers the descriptive overview of Diphtheria, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Diphtheria epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Diphtheria is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Diphtheria market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Diphtheria market

Diphtheria Market Report Insights

• Diphtheria Patient Population
• Diphtheria Therapeutic Approaches
• Diphtheria Pipeline Analysis
• Diphtheria Market Size and Trends
• Diphtheria Market Opportunities
• Impact of Upcoming Diphtheria Therapies

Diphtheria Market Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Diphtheria Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Diphtheria Market
• Diphtheria Drugs Uptake

Diphtheria Market Report Assessment

• Diphtheria Current Treatment Practices
• Diphtheria Unmet Needs
• Diphtheria Pipeline Product Profiles
• Diphtheria Market Attractiveness
• Diphtheria Market Drivers
• Diphtheria Market Barriers

Key Questions Answered In the Diphtheria Market Report:

Diphtheria Market Insights:

• What was the Diphtheria drug class share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Diphtheria total market size as well as market size by therapies across the 7MM during the forecast period (2020-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Diphtheria market size during the forecast period (2020-2034)?
• At what CAGR, the Diphtheria market is expected to grow by 7MM during the forecast period (2020-2034)?
• What would be the Diphtheria market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Diphtheria market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Diphtheria Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Diphtheria?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Diphtheria patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Diphtheria in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Diphtheria?
• Out of all 7MM countries, which country would have the highest prevalent population of Diphtheria during the forecast period (2020-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Diphtheria Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current options for the Diphtheria treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Diphtheria in the USA, Europe, and Japan?
• What are the Diphtheria marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Diphtheria?
• How many therapies are in-development by each company for Diphtheria treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Diphtheria treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Diphtheria therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diphtheria and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Diphtheria?
• What are the global historical and forecasted market of Diphtheria?

Reasons to buy Diphtheria Market Forecast Report

• The report will help in developing business strategies by understanding trends shaping and driving the Diphtheria market
• To understand the future market competition in the Diphtheria market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Diphtheria in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Diphtheria market
• To understand the future market competition in the Diphtheria market

Frequently Asked Questions

What is diphtheria?

Diphtheria is a contagious and potentially life-threatening bacterial infection. It is caused by infection with a toxin-producing strain of C. diphtheriae or, more rarely, Corynebacterium ulcerans or Corynebacterium pseudotuberculosis. It occurs in two forms: Respiratory diphtheria and cutaneous diphtheria. 

How is diphtheria transmitted?

Diphtheria is primarily transmitted through respiratory droplets from an infected person. When an infected person coughs, sneezes, or even talks, tiny droplets containing the diphtheria bacteria can be released into the air. These droplets can then be inhaled by others who are close to the infected person.

What are the types of Diphtheria Treatment available in the market?

Different types of treatment approaches involve the use of tetanus immune globulin, tetanus toxoid, diphtheria toxoid, and others.

Is there any approved drug for diphtheria?

Yes, there are several drugs approved for diphtheria, including LEQVIO. In December 2021, the US FDA approved LEQVIO (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C).

How the market of diphtheria is expected to change during the forecast period (2023–2034)?

With the recently launched drug and anticipated approval of therapies during the forecast period, it is expected to drive the market with a significant CAGR.

How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Diphtheria market.